高级检索
当前位置: 首页 > 详情页

Ifit1 Protects Against Lipopolysaccharide and D-galactosamine-Induced Fatal Hepatitis by Inhibiting Activation of the JNK Pathway.

文献详情

资源类型:
Pubmed体系:
机构: [1]School of Medicine, Nankai University, Tianjin, [2]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, [3]Department of Immunology, School of Basic Medicine, Peking Union Medical College, Beijing, People’s Republic of China [4]Immunology Research Center, National Health Research Institutes, Miaoli, Taiwan [5]Department of Cell and Molecular Biology, Scripps Research Institute, La Jolla, California
出处:
ISSN:

关键词: Ifit1 LPS fatal hepatitis TNF-α JNK

摘要:
Treatment of mice with lipopolysaccharide (LPS) and the liver-specific transcriptional inhibitor D-(+)-galactosamine (GalN) induces fatal hepatitis, which is mediated by tumor necrosis factor α (TNF-α) and characterized by massive hepatic apoptosis. Previous studies suggest that GalN increases the sensitivity to LPS/TNF-α, probably by blocking the transcription of protective factors, but the identity of most of these factors is still unclear. Here, we report that Ifit1 protects against LPS/GalN-induced fatal hepatitis. Forced expression of Ifit1 in hepatocytes significantly diminished TNF-α-mediated apoptosis. Moreover, targeted expression of Ifit1 in the liver by recombinant adeno-associated virus serotype 8 protected mice from LPS/GalN-induced lethal hepatitis, which was associated with the inhibition of TNF-α-mediated activation of the c-Jun N-terminal kinase (JNK)-Bim cascade. Furthermore, Ifit1 bound to a scaffolding protein Axin and inhibited its function to mediate JNK activation. Together, our data demonstrate that Ifit1 is a novel protective factor that inhibits LPS/GalN-induced (TNF-α-mediated) fatal hepatitis, suggesting that Ifit1 is a potential therapeutic target for treatment of inflammatory liver diseases. © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 传染病学 2 区 微生物学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 传染病学 2 区 微生物学
第一作者:
第一作者机构: [1]School of Medicine, Nankai University, Tianjin, [2]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University,
通讯作者:
通讯机构: [1]School of Medicine, Nankai University, Tianjin, [*1]School of Medicine, Nankai University, Tianjin 300071, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号